文献速递外周动脉疾病

下肢旁路手术中替代自体静脉移植物与单段大隐静脉的比较——单中心研究

Alternative Autologous Vein Grafts versus Single-Segment Great Saphenous Vein in Lower Extremity Bypass Surgery-Single-Center Study.
PubMed 文献 · Ann Vasc Surg · 2025-01-27

单中心回顾性队列研究纳入2019年4月至2023年6月接受腹股沟下旁路手术的患者,比较替代自体静脉移植物(AAVG)与单段大隐静脉(ssGSV)的通畅率和免截肢生存率。AAVG组65例(20.8%),ssGSV组247例(79.2%)。两组3年一期、一期辅助、二期通畅率及CLTI患者3年免截肢生存率均无显著差异。作者认为当ssGSV不可用时AAVG应作为首选移植物。

要点

  • AAVG组3年一期通畅率59.3%±8.2% vs ssGSV组69.2%±3.8%,P=0.113,无显著差异。
  • AAVG组再手术率35.4%(23/65)高于ssGSV组10.5%(26/247),P<0.001。
  • CLTI患者3年免截肢生存率AAVG组70.7%±7.9% vs ssGSV组54.6%±4.8%,P=0.273。

核心结论

  • 当单段大隐静脉不可用时,替代自体静脉移植物应作为首选移植物。
  • 尽管再干预率更高,替代自体静脉移植物的中期通畅率与单段大隐静脉移植物无差异。

研究设计与样本

  • 单中心回顾性队列研究,纳入2019年4月至2023年6月所有使用替代自体静脉移植物(臂静脉、拼接臂静脉或臂-腿静脉)和单段大隐静脉行腹股沟下旁路手术的患者。
  • 替代自体静脉移植物组65例(20.8%),单段大隐静脉组247例(79.2%)。
  • 研究终点为通畅率和免截肢生存率。

主要发现

  • 慢性肢体威胁性缺血是最常见手术指征:AAVG组54/65(83.1%)vs ssGSV组170/247(68.8%)。
  • 急性肢体缺血:AAVG组6/65(9.2%)vs ssGSV组28/247(11.3%);跛行仅见于ssGSV组(AAVG组0/65,0% vs ssGSV组44/247,17.8%)。
  • 再手术:AAVG组23/65(35.4%)vs ssGSV组26/247(10.5%),P<0.001。
  • 拼接静脉移植物占AAVG旁路的87.7%(57/65)。
  • 中位随访时间:AAVG组20.1个月,ssGSV组27.5个月。

临床怎么用

  • 作者认为当单段大隐静脉不可用时,替代自体静脉移植物应作为首选移植物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies comparing alternative autologous vein grafts (AAVGs) to single-segment great saphenous vein (ssGSV) grafts report mixed results. The status of AAVG as first choice when ssGSV is unavailable is not unequivocal based on current evidence. Our study compares results between AAVG and ssGSV in lower extremity bypass (LEB) surgery. METHODS: A single-center retrospective cohort study involving all patients who underwent infrainguinal bypass using AAVG (arm veins, spliced arm, or arm-leg veins) and ssGSV from April 2019 to June 2023. Study endpoints were patency rates and amputation-free survival (AFS). RESULTS: There were 65 (20.8%) patients in the AAVG group, 247 (79.2%) in the ssGSV group. Chronic limb-threatening ischemia (CLTI) was the most frequent indication for surgery (AAVG 54/65, 83.1% vs. ssGSV 170/247, 68.8%), followed by acute limb ischemia (ALI) (AAVG 6/65, 9.2% vs. ssGSV 28/247, 11.3%); claudicants were presented only in the ssGSV group (AAVG 0/65, 0% vs. ssGSV 44/247, 17.8%). More redo operations occurred in AAVG than in the ssGSV group (23/65, 35.4% vs. 26/247, 10.5%; P < 0.001). Spliced vein grafts represented 87.7% (57/65) of AAVG bypasses. The median follow-up was 20.1 months for the AAVG group and 27.5 for the ssGSV group. Three-year patency rates between AAVG versus ssGSV: primary patency (PP) 59.3% ± 8.2% versus 69.2% ± 3.8%, P = 0.113; primary assisted patency (PAP) 75.2% ± 7.1% versus 73.5% ± 3.4%, P = 0.790; secondary patency (SP) 74.9% ± 7.1% versus 74.4% ± 3.4%, P = 0.667; did not display significant difference between groups nor did 3-year AFS in CLTI patients; 70.7% ± 7.9% versus 54.6% ± 4.8%; P = 0.273. CONCLUSION: AAVGs should be the first conduit choice when ssGSV is unavailable. Mid-term patency rates do not differ from those of ssGSV grafts despite higher reintervention rate.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Biroš E, Staffa R, Krejčí M, et al. Alternative Autologous Vein Grafts versus Single-Segment Great Saphenous Vein in Lower Extremity Bypass Surgery-Single-Center Study. Ann Vasc Surg. 2025. PMID: 39880284. doi:10.1016/j.avsg.2025.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。